Scopolamine Patch Should Not Be Used in a 9-Year-Old Child
The scopolamine transdermal patch is not approved for use in children and should be avoided in this 9-year-old patient. The FDA drug label explicitly states "It is not known if scopolamine transdermal system is safe and effective in children" and further warns that "pediatric patients are particularly susceptible to the adverse reactions of scopolamine, including mydriasis, hallucinations, amblyopia and drug withdrawal syndrome" 1.
Why This Matters
The evidence strongly discourages pediatric use:
FDA Position (Highest Priority Evidence)
- No established safety or efficacy in children - the drug label clearly states this limitation 1
- Heightened vulnerability - children experience more severe adverse reactions than adults, including neurologic and psychiatric complications 1
- The FDA specifically identifies pediatric patients as a high-risk population for serious side effects
Documented Pediatric Adverse Events
The research literature confirms significant safety concerns:
- Severe delirium and psychosis: A case report describes a 4-year-old who developed acute cognitive deterioration, hallucinations, aggressive behavior, hyperactivity, and incoherent speech from a scopolamine patch 2
- Visual impairment: Two children (ages 5 and 7) experienced dilated pupils, reduced near visual acuity, and impaired accommodation that resolved only after patch removal 3
- Cumulative toxicity risk: Effects may accumulate over time, and many pediatric patients cannot communicate visual or cognitive difficulties 3
Systematic Review Recommendation
A 2018 systematic review using Johns Hopkins Research Evidence Appraisal methodology concluded that clinicians should avoid administering scopolamine to pediatric patient populations 4. This represents a clear consensus recommendation against pediatric use.
Important Clinical Caveats
Off-label use for drooling: While some studies show scopolamine patches reduced drooling in neurologically impaired children 5, 6, these represent off-label use in a specialized population with careful monitoring. This does not establish general safety for routine pediatric use, and the risk-benefit calculation differs substantially from typical indications like motion sickness or postoperative nausea.
The anticholinergic effects are particularly dangerous in children because they can cause:
- Central nervous system toxicity (hallucinations, delirium, confusion)
- Visual disturbances that children may not report
- Drug withdrawal syndrome upon discontinuation
- Unpredictable responses due to developing physiology
Alternative Approach
For a 9-year-old requiring antiemetic therapy, consider age-appropriate alternatives with established pediatric safety profiles rather than using an unapproved medication with documented serious adverse events in this age group.